Skip to content

Clinical trials

Observational Language Development Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Language Development Disorders Phase: Observational Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20131
20141
20181
20192
20212
20221
20232
20254

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Recruiting6
Not yet recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
IRCCS Eugenio Medea2
Indonesia University2
Bartosz M. Radtke1
Centre Hospitalier Universitaire, Amiens1
Children's Hospital of Fudan University1
Cliniques universitaires Saint-Luc- Université Catholique de Louvain1
Hadassah Medical Organization1
Lille Catholic University1
Loma Linda University1
National Institute on Deafness and Other Communication Disorders (NIDCD)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Language Development Disorders15
Learning Disabilities4
Autism Spectrum Disorder3
Language Disorders3
Autistic Disorder2
Developmental Disabilities2
Psychomotor Disorders2
Attention Deficit Disorder with Hyperactivity1
Auditory Perceptual Disorders1
Communication Disorders1

Trials

Showing 51 to 15 of 15. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.